Australia's most trusted
source of pharma news
Posted 8 July 2026 PM
Just a month after starting a new cohort, Sydney-based Imugene is reporting two complete responses in new cancers.
On 28 May this year Imugene expanded its Phase 1b trial of off-the-shelf CAR T therapy azercabtagene zapreleucel (azer-cel) in patients with Relapsed/Refractory Non-Hodgkin Lymphoma and B-cell Acute Lymphoblastic Leukemia to include a cohort that had failed prior BTK inhibitor therapy, to see whether concurrent treatment with a BTK inhibitor may improve the activity of azer-cel.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.